Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alliance Pharma's Enterprise Value is £288.5 Mil.
Alliance Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £2.3 Mil. Therefore, Alliance Pharma's EV-to-EBIT ratio for today is 124.53.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Alliance Pharma's Enterprise Value is £288.5 Mil.
Alliance Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was £12.5 Mil. Therefore, Alliance Pharma's EV-to-EBITDA ratio for today is 23.07.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Alliance Pharma's Enterprise Value is £288.5 Mil.
Alliance Pharma's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was £170.0 Mil. Therefore, Alliance Pharma's EV-to-Revenue ratio for today is 1.70.
Alliance Pharma Enterprise Value Historical Data
The historical data trend for Alliance Pharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alliance Pharma's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Alliance Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alliance Pharma's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alliance Pharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Alliance Pharma's Enterprise Value falls into.
Alliance Pharma Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Alliance Pharma's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alliance Pharma (LSE:APH) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Alliance Pharma's current Enterprise Value is £288.5 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Alliance Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £2.3 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Alliance Pharma's current Enterprise Value is £288.5 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Alliance Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was £12.5 Mil.
Alliance Pharma's current Enterprise Value is £288.5 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Alliance Pharma's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was £170.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alliance Pharma Enterprise Value Related Terms
Thank you for viewing the detailed overview of Alliance Pharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:APH has been successfully added to your 